基于结构的药物设计中扩散模型的通用约束性亲和指导
Yue Jian1, Curtis Wu2, Danny Reidenbach3
1Department of Chemical & Biomolecular Engineering, University of California, Berkeley, Berkeley, California 94720, United States.
我们开发了BADGER,这是一个框架,用于增强基于结构的药物设计的扩散模型. 它通过指导分子生成来提高联体蛋白结合亲和力,从而导致更好的药物候选者.
科学领域:
- 计算化学是一种计算化学.
- 药物发现 药物发现
- 医学中的人工智能
背景情况:
- 基于结构的药物设计 (SBDD) 使用计算方法创建针对特定蛋白质的分子.
- 扩散模型在SBDD中显示出希望,但往往缺乏对结合亲和力的精确控制.
- 现有的模型可能在联体生成过程中不够优先考虑结合亲和力.
研究的目的:
- 在SBDD中引入BADGER,这是SBDD中扩散模型的新型约束亲和指导框架.
- 为了提高扩散模型的控制和有效性,在产生高亲缘关系联体方面.
- 为了使药物候选物的设计具有改进的结合特性.
主要方法:
- BADGER采用两种策略:基于梯度的亲和信号的分类器指导和将亲和条件纳入培训的无分类器指导.
- 该框架被设计为现有扩散模型的插入运行模块.
- 扩展到多重约束指导,优化结合亲和力,药物相似性 (QED) 和合成可访问性 (SA).
主要成果:
- 与以前的方法相比,BADGER在联体蛋白结合亲和力中表现出高达60%的改善.
- 通过结合亲和力引导实现可控制的配体生成.
- 通过优化多个约束,成功设计了现实的和可合成的候选药物.
结论:
- 贝杰 (BADGER) 在基于结构的药物设计中显著提升了扩散模型的能力.
- 该框架提供了一个强大的工具,用于生成强效和特定的候选药物.
- 多重约束优化使得能够设计具有高结合亲和力的类似药物和可合成分子.
更多相关视频
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
10:22Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis
Published on: August 15, 2013
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Affinity and Avidity
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
